The Estée Lauder Companies has announced a strategic collaboration with biotech firm Serpin Pharma to explore how anti-inflammatory research can enhance cosmetic formulations, offering longevity benefits in skin care.
The partnership aims to accelerate product innovation by combining Serpin Pharma’s expertise in Serine Protease Inhibitors with Estée Lauder’s track record of commercializing cutting-edge beauty solutions.
Carl Haney, Executive Vice President of Global Innovation and R&D at The Estée Lauder Companies, highlighted the collaboration’s potential. “This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery. In partnership with Serpin Pharma, we’re exploring powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for our prestige beauty consumers worldwide.”
The alliance underscores Estée Lauder’s commitment to leveraging biotech advancements to deliver high-performance, science-backed skincare products to global consumers.
Related Topics:
